Investigation of genetic and acquired risk factors linked to development of atherosclerosis-related diseases; exploring of genetic polymorphisms associated with inflammation, oxidative stress and dyslipidemia; evaluation of genetic polymorphism of enzymes involved in metabolism of xenobiotics; studies of gene expression of specific genes involved in inflammation and atherosclerosis development using Real-time PCR method; advanced lipid status assessment – measuring of lipid transfer proteins, lipoprotein’s receptors and their regulators, as well as electrophoretic characterization of lipoprotein subclasses; investigation of lipid status in patients with subclinical hypothyroidism; estimation of redox balance; research on oxidative stress and antioxidative defence markers; evaluation of clinical and analytical characteristics of markers of systemic oxidative stress (oxidatively modified DNA lesions and mechanisms of reparation); assessment of antioxidative capacity of bilirubin and uric acid; measuring of adipocytokines and evaluation of their relationships with lipid status, oxidative stress and inflammatory markers; structural and functional analysis of molecular markers of complex and inherited diseases (chronic obstructive pulmonary disease, asthma, diabetes, malignant diseases, alpha-1-antitrypsin deficiency); determination of cholesterol synthesis and absorption markers by GC-FID and LC-MS/MS methods; monitoring the status of vitamin D and its metabolites and determination of their relationship with the occurrence, and development of malignant diseases as well as metabolic disorders; estimation of biomarkers as possible diagnostic, prognostic and predictive indicators of cardiovascular diseases, malignancies, diabetes and other pathological conditions (chronic kidney disease, preeclampsia, Gaucher disease, disturbances in hypothalamic-pituitary-adrenal axis, thyroid gland disorders); economic evaluation (cost-effectiveness analyses) of traditional and new diagnostic markers, new diagnostic procedures and laboratory tests; development of economic models for inclusion of new biomarkers in risk prediction for various diseases; estimation of butyrylcholinesterase activity as a predictor of mortality in hemodialysis patients; evaluation of novel technologies in hematology and hemostasis; evaluation and clinical application of new hematological indices; hypercoagulable states and thrombosis; clinical use of coagulation activation markers; antiphospholipid syndrome – diagnosis and hematological complications; laboratory control of anticoagulant therapy; use of new anticoagulants; following of therapy and complications in hemophilia; biochemistry of sport; hematology of sport.